Integrated network pharmacology approaches combined with Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis and bioinformatics interrogation demonstrated that 1,25(OH)2D3 may potentiate sorafenib chemosensitivity in HCC through the modulation of the FoxO signaling pathway, with FOXO3A identified as a pivotal regulatory mediator, a key protein in the FoxO signaling pathway and a member of the Forkhead family of transcription factors; it plays a crucial role in liver cancer, breast cancer, colon cancer, and other cancers [13]. The gene discussed is FOXO3; the disease is breast cancer.